SEARCH

SEARCH BY CITATION

References

  • 1
    Walboomers JM,Jacobs MV,Manos MM,Bosch FX,Kummer JA,Shah KV,Snijders PJ,Peto J,Meijer CJ,Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 1219.
  • 2
    Munoz N,Bosch FX,de Sanjose S,Herrero R,Castellsague X,Shah KV,Snijders PJ,Meijer CJ. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 51827.
  • 3
    Bosch FX,Lorincz A,Munoz N,Meijer CJ,Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55: 24465.
  • 4
    Bulkmans NW,Rozendaal L,Snijders PJ,Voorhorst FJ,Boeke AJ,Zandwijken GR,van Kemenade FJ,Verheijen RH,Groningen K,Boon ME,Keuning HJ,van Ballegooijen M, et al. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int J Cancer 2004; 110: 94101.
  • 5
    Bulkmans NW,Rozendaal L,Voorhorst FJ,Snijders PJ,Meijer CJ. Long-term protective effect of high-risk human papillomavirus testing in population-based cervical screening. Br J Cancer 2005; 92: 18002.
  • 6
    Cuzick J,Szarewski A,Cubie H,Hulman G,Kitchener H,Luesley D,McGoogan E,Menon U,Terry G,Edwards R,Brooks C,Desai M, et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 2003; 362: 18716.
  • 7
    Ronco G,Giorgi-Rossi P,Carozzi F,Dalla PP,Del Mistro A,De Marco L,De Lillo M,Naldoni C,Pierotti P,Rizzolo R,Segnan N,Schincaglia P, et al. Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. Lancet Oncol 2006; 7: 54755.
  • 8
    Sherman ME,Lorincz AT,Scott DR,Wacholder S,Castle PE,Glass AG,Mielzynska-Lohnas I,Rush BB,Schiffman M. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst 2003; 95: 4652.
  • 9
    Bulkmans N,Berkhof J,Rozendaal L,van Kemenade F,Boeke A,Bulk S,Voorhorst F,Verheijen R,van Groningen K,Boon M,Ruitinga W,van Ballegooijen M, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007; 370: 176472.
  • 10
    Naucler P,Ryd W,Tornberg S,Strand A,Wadell G,Elfgren K,Radberg T,Strander B,Forslund O,Hansson BG,Rylander E,Dillner J. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007; 357: 158997.
  • 11
    Mayrand MH,Duarte-Franco E,Rodrigues I,Walter SD,Hanley J,Ferenczy A,Ratnam S,Coutlee F,Franco EL. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007; 357: 157988.
  • 12
    Snijders PJ,van den Brule AJ,Meijer CJ. The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity. J Pathol 2003; 201: 16.
  • 13
    Swan DC,Tucker RA,Tortolero-Luna G,Mitchell MF,Wideroff L,Unger ER,Nisenbaum RA,Reeves WC,Icenogle JP. Human papillomavirus (HPV) DNA copy number is dependent on grade of cervical disease and HPV type. J Clin Microbiol 1999; 37: 10304.
  • 14
    Josefsson AM,Magnusson PK,Ylitalo N,Sorensen P,Qwarforth-Tubbin P,Andersen PK,Melbye M,Adami HO,Gyllensten UB. Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study. Lancet 2000; 355: 218993.
  • 15
    Ylitalo N,Sorensen P,Josefsson AM,Magnusson PK,Andersen PK,Ponten J,Adami HO,Gyllensten UB,Melbye M. Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case-control study. Lancet 2000; 355: 21948.
  • 16
    van Duin M,Snijders PJ,Schrijnemakers HF,Voorhorst FJ,Rozendaal L,Nobbenhuis MA,van den Brule AJ,Verheijen RH,Helmerhorst TJ,Meijer CJ. Human papillomavirus 16 load in normal and abnormal cervical scrapes: an indicator of CIN II/III and viral clearance. Int J Cancer 2002; 98: 5905.
  • 17
    Monnier-Benoit S,Dalstein V,Riethmuller D,Lalaoui N,Mougin C,Pretet JL. Dynamics of HPV16 DNA load reflect the natural history of cervical HPV-associated lesions. J Clin Virol 2006; 35: 2707.
  • 18
    Moberg M,Gustavsson I,Wilander E,Gyllensten U. High viral loads of human papillomavirus predict risk of invasive cervical carcinoma. Br J Cancer 2005; 92: 8914.
  • 19
    Moberg M,Gustavsson I,Gyllensten U. Type-specific associations of human papillomavirus load with risk of developing cervical carcinoma in situ. Int J Cancer 2004; 112: 8549.
  • 20
    Lorincz AT,Castle PE,Sherman ME,Scott DR,Glass AG,Wacholder S,Rush BB,Gravitt PE,Schussler JE,Schiffman M. Viral load of human papillomavirus and risk of CIN3 or cervical cancer. Lancet 2002; 360: 2289.
  • 21
    Schlecht NF,Trevisan A,Duarte-Franco E,Rohan TE,Ferenczy A,Villa LL,Franco EL. Viral load as a predictor of the risk of cervical intraepithelial neoplasia. Int J Cancer 2003; 103: 51924.
  • 22
    Sherman ME,Wang SS,Wheeler CM,Rich L,Gravitt PE,Tarone R,Schiffman M. Determinants of human papillomavirus load among women with histological cervical intraepithelial neoplasia 3: dominant impact of surrounding low-grade lesions. Cancer Epidemiol Biomarkers Prev 2003; 12: 103844.
  • 23
    Castle PE,Schiffman M,Wheeler CM. Hybrid capture 2 viral load and the 2-year cumulative risk of cervical intraepithelial neoplasia grade 3 or cancer. Am J Obstet Gynecol 2004; 191: 15907.
  • 24
    Sun CA,Lai HC,Chang CC,Neih S,Yu CP,Chu TY. The significance of human papillomavirus viral load in prediction of histologic severity and size of squamous intraepithelial lesions of uterine cervix. Gynecol Oncol 2001; 83: 959.
  • 25
    Snijders PJ,Hogewoning CJ,Hesselink AT,Berkhof J,Voorhorst FJ,Bleeker MC,Meijer CJ. Determination of viral load thresholds in cervical scrapings to rule out CIN 3 in HPV 16, 18, 31 and 33-positive women with normal cytology. Int J Cancer. 2006; 119: 11027.
  • 26
    Berkhof J,de Bruijne MC,Zielinski GD,Bulkmans NW,Rozendaal L,Snijders PJ,Verheijen RH,Meijer CJ. Evaluation of cervical screening strategies with adjunct high-risk human papillomavirus testing for women with borderline or mild dyskaryosis. Int J Cancer 2006; 118: 175968.
  • 27
    Bulk S,van Kemenade FJ,Rozendaal L,Meijer CJ. The Dutch CISOE-a framework for cytology reporting increases efficacy of screening upon standardisation since 1996. J Clin Pathol 2004; 57: 38893.
  • 28
    Solomon D,Davey D,Kurman R,Moriarty A,O'Connor D,Prey M,Raab S,Sherman M,Wilbur D,Wright TJr,Young N. The 2001 Bethesda System: terminology for reporting results of cervical cytology. J AMA 2002; 287: 211419.
  • 29
    Berkhof J,Bulkmans NW,Bleeker MC,Bulk S,Snijders PJ,Voorhorst FJ,Meijer CJ. Human papillomavirus type-specific 18-month risk of high-grade cervical intraepithelial neoplasia in women with a normal or borderline/mildly dyskaryotic smear. Cancer Epidemiol Biomarkers Prev 2006; 15: 126873.
  • 30
    van den Brule AJ,Pol R,Fransen-Daalmeijer N,Schouls LM,Meijer CJ,Snijders PJ. GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J Clin Microbiol 2002; 40: 77987.
  • 31
    Hesselink AT,van den Brule AJ,Groothuismink ZM,Molano M,Berkhof J,Meijer CJ,Snijders PJ. Comparison of three different PCR methods for quantifying human papillomavirus type 16 DNA in cervical scrape specimens. J Clin Microbiol 2005; 43: 486871.
  • 32
    Bleeker MC,Hogewoning CJ,Voorhorst FJ,van den Brule AJ,Berkhof J,Hesselink AT,Lettink M,Starink TM,Stoof TJ,Snijders PJ,Meijer CJ. HPV-associated flat penile lesions in men of a non-STD hospital population: less frequent and smaller in size than in male sexual partners of women with CIN. Int J Cancer. 2005; 113: 3641.
  • 33
    Kulasingam SL,Hughes JP,Kiviat NB,Mao C,Weiss NS,Kuypers JM,Koutsky LA. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA 2002; 288: 174957.
  • 34
    Franco EL,Ferenczy A. Assessing gains in diagnostic utility when human papillomavirus testing is used as an adjunct to papanicolaou smear in the triage of women with cervical cytologic abnormalities. Am J Obstet Gynecol 1999; 181: 3826.
  • 35
    Arbyn M,Sasieni P,Meijer CJ,Clavel C,Koliopoulos G,Dillner J. Chapter 9: clinical applications of HPV testing: a summary of meta-analyses. Vaccine 2006; 24( Suppl 3): S78S89.
  • 36
    Cuzick J,Clavel C,Petry KU,Meijer CJ,Hoyer H,Ratnam S,Szarewski A,Birembaut P,Kulasingam S,Sasieni P,Iftner T. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006; 119: 1095101.
  • 37
    Gravitt PE,Kovacic MB,Herrero R,Schiffman M,Bratti C,Hildesheim A,Morales J,Alfaro M,Sherman ME,Wacholder S,Rodriguez AC,Burk RD. High load for most high risk human papillomavirus genotypes is associated with prevalent cervical cancer precursors but only HPV16 load predicts the development of incident disease. Int J Cancer 2007; 121: 278793.
  • 38
    Moberg M,Gustavsson I,Wilander E,Gyllensten U. High viral loads of human papillomavirus predict risk of invasive cervical carcinoma. Br J Cancer 2005; 92: 8914.
  • 39
    Ylitalo N,Josefsson A,Melbye M,Sorensen P,Frisch M,Andersen PK,Sparen P,Gustafsson M,Magnusson P,Ponten J,Gyllensten U,Adami HO. A prospective study showing long-term infection with human papillomavirus 16 before the development of cervical carcinoma in situ. Cancer Res 2000; 60: 602732.
  • 40
    Hesselink AT,Bulkmans NW,Berkhof J,Lorincz AT,Meijer CJ,Snijders PJ. Cross-sectional comparison of an automated hybrid capture 2 assay and the consensus GP5+/6+ PCR method in a population-based cervical screening program. J Clin Microbiol 2006; 44: 36805.
  • 41
    Ronco G,Giorgi-Rossi P,Carozzi F,Dalla PP,Del Mistro A,De Marco L,De Lillo M,Naldoni C,Pierotti P,Rizzolo R,Segnan N,Schincaglia P, et al. Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. Lancet Oncol 2006; 7: 54755.
  • 42
    Castle PE,Schiffman M,Burk RD,Wacholder S,Hildesheim A,Herrero R,Bratti MC,Sherman ME,Lorincz A. Restricted cross-reactivity of hybrid capture 2 with nononcogenic human papillomavirus types. Cancer Epidemiol Biomarkers Prev 2002; 11: 13949.
  • 43
    Cuzick J,Mayrand MH,Ronco G,Snijders P,Wardle J. Chapter 10: new dimensions in cervical cancer screening. Vaccine 2006; 24( Suppl 3): S90S97.
  • 44
    Bulk S,Bulkmans NW,Berkhof J,Rozendaal L,Boeke AJ,Verheijen RH,Snijders PJ,Meijer CJ. Risk of high-grade cervical intra-epithelial neoplasia based on cytology and high-risk HPV testing at baseline and at 6-months. Int J Cancer 2007; 121: 3617.
  • 45
    Khan MJ,Castle PE,Lorincz AT,Wacholder S,Sherman M,Scott DR,Rush BB,Glass AG,Schiffman M. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005; 97: 10729.
  • 46
    Castle PE,Solomon D,Schiffman M,Wheeler CM. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J Natl Cancer Inst 2005; 97: 106671.
  • 47
    Molden T,Kraus I,Karlsen F,Skomedal H,Nygard JF,Hagmar B. Comparison of human papillomavirus messenger RNA and DNA detection: a cross-sectional study of 4,136 women >30 years of age with a 2-year follow-up of high-grade squamous intraepithelial lesion. Cancer Epidemiol Biomarkers Prev 2005; 14: 36772.
  • 48
    Dray M,Russell P,Dalrymple C,Wallman N,Angus G,Leong A,Carter J,Cheerala B. p16(INK4a) as a complementary marker of high-grade intraepithelial lesions of the uterine cervix. I: experience with squamous lesions in 189 consecutive cervical biopsies. Pathology 2005; 37: 11224.
  • 49
    Cuschieri KS,Whitley MJ,Cubie HA. Human papillomavirus type specific DNA and RNA persistence–implications for cervical disease progression and monitoring. J Med Virol 2004; 73: 6570.
  • 50
    Henken FE,Wilting SM,Overmeer RM,van Rietschoten JG,Nygren AO,Errami A,Schouten JP,Meijer CJ,Snijders PJ,Steenbergen RD. Sequential gene promoter methylation during HPV-induced cervical carcinogenesis. Br J Cancer 2007; 97: 145764.
  • 51
    Wilting SM,Snijders PJ,Meijer GA,Ylstra B,van den Ijssel PR,Snijders AM,Albertson DG,Coffa J,Schouten JP,van de Wiel MA,Meijer CJ,Steenbergen RD. Increased gene copy numbers at chromosome 20q are frequent in both squamous cell carcinomas and adenocarcinomas of the cervix. J Pathol 2006; 209: 22030.